Overall, the current experience suggests that the favorable efficacy/safety profile of Pembro may place this drug as a first choice in refractory PitNETs, especially in the presence of some tumor characteristics—PDL1 expression or MMRd/elevated TMB. The gene discussed is CD274; the disease is neoplasm.